← Back to Search

eHealth Genetic Testing for Cancer (eReach2 Trial)

N/A
Recruiting
Led By Angela R Bradbury, MD
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
No prior germline genetic testing
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

eReach2 Trial Summary

This trial will compare the effects of standard genetic counseling to a self-directed web-based intervention.

Who is the study for?
This trial is for adults who speak English and meet the guidelines for genetic testing due to cancer risk, but haven't had germline genetic testing before. It's not suitable for those with uncontrolled mental conditions or severe physical impairments that affect communication or understanding of the study.Check my eligibility
What is being tested?
The study tests if web-based eHealth interventions can replace traditional in-person counseling by a genetic counselor without compromising care quality. Participants are randomly assigned to either standard care or self-directed online sessions before and after genetic testing.See study design
What are the potential side effects?
Since this trial involves non-medical interventions like web-based education and counseling, typical medical side effects are not expected. However, participants may experience emotional or psychological responses to information about their cancer risk.

eReach2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have not had genetic testing for inherited conditions.

eReach2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The KnowGene Scale
Uptake of Genetic Services
Secondary outcome measures
Decisional Regret Scale
Impact of Events Scale (IES)
Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)
+3 more

eReach2 Trial Design

4Treatment groups
Experimental Treatment
Group I: ARM DExperimental Treatment2 Interventions
Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention. Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention.
Group II: ARM CExperimental Treatment2 Interventions
Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention. Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor.
Group III: ARM BExperimental Treatment2 Interventions
Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor. Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention.
Group IV: ARM AExperimental Treatment1 Intervention
Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor. Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
385 Previous Clinical Trials
143,901 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,926,347 Total Patients Enrolled
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
104,095 Total Patients Enrolled

Media Library

eHealth Delivery Alternative Clinical Trial Eligibility Overview. Trial Name: NCT05427240 — N/A
Cancer Research Study Groups: ARM D, ARM A, ARM B, ARM C
Cancer Clinical Trial 2023: eHealth Delivery Alternative Highlights & Side Effects. Trial Name: NCT05427240 — N/A
eHealth Delivery Alternative 2023 Treatment Timeline for Medical Study. Trial Name: NCT05427240 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this experimentation still open?

"Affirmative, according to clinicaltrials.gov the trial was initially shared on September 28th 2022 and had its most recent update three days later. It is now recruiting 1000 patients from one major centre."

Answered by AI

What is the utmost number of individuals participating in this investigation?

"Affirmative. According to the data provided on clinicaltrials.gov, this research is presently seeking volunteers; it was initially posted on September 28th 2022 and recently updated October 3rd 2022. This investigation demands a total of 1000 participants from one location."

Answered by AI

What aim is this clinical trial hoping to accomplish?

"The primary outcome of the trial, which will be observed over a period of one year on average, is to measure patient progress with The KnowGene Scale. Secondary outcomes include Provider Time (measured in minutes spent per patient), MICRA (Change in Uncertainty - Score Range = 0-85; Lower score indicates better outcome) and PROMIS scores for Change in General Depression (Score Range = 4-20; again lower indicating improved results)."

Answered by AI
~455 spots leftby Jul 2025